MAP2K1 and colorectal cancer: In a two-dimensional growth model, we found that treatment of the colorectal cancer cell line, HCT116, with the MEK1/2 inhibitor, PD0325901, was more effective in suppressing cell proliferation in combination with ERK5 inhibitor, XMD8-92, compared with either treatment alone (Fig. 6a,b).